Research progress on the synthesis and pharmacology of 1, 3, 4-oxadiazole and 1, 2, 4-oxadiazole derivatives: a mini review

JJ Wang, W Sun, WD Jia, M Bian… - Journal of Enzyme …, 2022 - Taylor & Francis
Oxadiazole is a five-membered heterocyclic compound containing two nitrogen atoms and
one oxygen atom. The 1, 3, 4-oxadiazole and 1, 2, 4-oxadiazole have favourable physical …

[HTML][HTML] Recent updates on structural insights of MAO-B inhibitors: A review on target-based approach

GS Baweja, S Gupta, B Kumar, P Patel, V Asati - Molecular Diversity, 2023 - Springer
Parkinson's disease is a neurodegenerative disorder characterized by slow movement,
tremors, and stiffness caused due to loss of dopaminergic neurons caused in the brain's …

Design, Synthesis, and In Vitro and In Silico Approaches of Novel Indanone Derivatives as Multifunctional Anti-Alzheimer Agents

BN Sağlık, S Levent, D Osmaniye, AE Evren… - ACS …, 2022 - ACS Publications
Alzheimer's disease (AD) is a neurological, progressive illness that typically affects the
elderly and is clinically distinguished by memory and cognitive decline. Due to a number of …

[HTML][HTML] Synthesis of novel benzothiazole derivatives and investigation of their enzyme inhibitory effects against Alzheimer's disease

Ş Karaca, D Osmaniye, BN Sağlık, S Levent, S Ilgın… - RSC …, 2022 - pubs.rsc.org
The use of dual acetylcholinesterase (AChE)–monoamine oxidase B (MAO-B) inhibitors is a
new approach in the treatment of Alzheimer disease (AD). In this work, 14 new …

Design, synthesis, biological activity, molecular docking, and molecular dynamics of novel benzimidazole derivatives as potential AChE/MAO‐B dual inhibitors

D Osmaniye, AE Evren, BN Sağlık, S Levent… - Archiv der …, 2022 - Wiley Online Library
To develop new acetylcholinesterase (AChE)–monoamine oxidase‐B (MAO‐B) dual
inhibitors against Alzheimer's disease, the benzimidazole ring, which has a propargyl side …

Challenging the anticolorectal cancer capacity of quinoxaline-based scaffold via triazole ligation unveiled new efficient dual VEGFR-2/MAO-B inhibitors

MS Ayoup, A Ammar, H Abdel-Hamid, A Amer… - Bioorganic …, 2024 - Elsevier
Monoamine oxidases (MAOs) and vascular endothelial growth factor receptor-2 (VEGFR-2)
are promoters of colorectal cancer (CRC) and central signaling nodes in epithelial …

[HTML][HTML] Therapeutic potential of 1, 3, 4-oxadiazoles as potential lead compounds for the treatment of Alzheimer's disease

S Naseem, A Temirak, A Imran, S Jalil, S Fatima… - RSC …, 2023 - pubs.rsc.org
Monoamine oxidase and cholinesterase enzymes are important targets for the treatment of
several neurological diseases especially depression, Parkinson disease and Alzheimer's …

“Urea to urea” approach: access to unsymmetrical ureas bearing pyridyl substituents

SO Kasatkina, KK Geyl, SV Baykov… - Advanced Synthesis …, 2022 - Wiley Online Library
A protocol for the synthesis of unsymmetrical ureas substituted by pyridyl/quinolinyl moiety
has been developed. This method concluded in metal‐and base‐free reamination of N, N …

[HTML][HTML] Novel thiosemicarbazone derivatives: In vitro and in silico evaluation as potential MAO-B inhibitors

D Osmaniye, B Kurban, BN Sağlık, S Levent, Y Özkay… - Molecules, 2021 - mdpi.com
MAO-B inhibitors are frequently used in the treatment of neurodegenerative diseases such
as Parkinson's and Alzheimer's. Due to the limited number of compounds available in this …

Novel imidazole derivatives as potential aromatase and monoamine oxidase-B inhibitors against breast cancer

D Osmaniye, S Levent, BN Sağlık… - New Journal of …, 2022 - pubs.rsc.org
In this study, we developed a series of new aromatase MAO-B dual inhibitors against breast
cancer. Aromatase inhibitors are the most commonly used drugs clinically for breast cancer …